Vietnam Biosimilars Market Overview, 2030

Market dynamics are increasingly shaped by the entry of generics companies alongside established biopharmaceutical players, intensifying competition and driving innovation in manufacturing processes. The therapeutic landscape shows particular strength in monoclonal antibodies, insulin products, and erythropoietin biosimilars, with emerging opportunities in complex biologics as regulatory pathways mature. Geographically, Asia-Pacific markets are emerging as significant growth drivers due to expanding healthcare infrastructure and increasing disease burden. The sector faces substantial challenges that continue to limit market penetration. The development of biosimilars is intricate and costly, demanding significant investments, technical expertise, clinical trial capabilities, and adherence to stringent quality standards, unlike traditional generic drugs. Market access of biosimilar monoclonal antibodies is hampered by six barriers: the manufacturing process, the regulatory process, intellectual property rights, lack of incentive, the impossibility of substitution and the innovator's reach. Evaluation of applications for biosimilar approval is challenging and product assessment difficult, with training being problematic for those with limited experience. Solutions are emerging through enhanced regulatory harmonization, with agencies developing clearer guidelines for interchangeability and post-marketing surveillance. Manufacturers are investing in advanced analytical technologies and establishing strategic partnerships to overcome technical barriers. Healthcare systems are implementing policies promoting biosimilar adoption through physician education programs and value-based procurement strategies, while addressing patient confidence through transparent communication about safety and efficacy equivalence.

The biosimilars market experiences robust growth driven by compelling economic imperatives and evolving healthcare dynamics. The primary drivers of the biosimilars market are increasing incidence of chronic diseases, with Latin American countries facing significant increases in healthcare expenditure, driven largely by population growth and aging, and the rising prevalence of cancer and other chronic diseases. The increasing prevalence of cancer and the aging population are the main drivers of market growth, creating unprecedented demand for accessible biological therapies across diverse therapeutic areas. Cost containment remains the paramount driver as healthcare systems globally struggle with budget constraints. The World Health Organization recognizes biosimilars as key drivers for expanding access to essential biological medicines, while through competition with the original product, biosimilars have been able to drive down prices and relieve the healthcare system without changing overall efficacy. Regulatory modernization accelerates market expansion through streamlined approval pathways and enhanced confidence in biosimilar quality. Patent cliff phenomena create strategic windows as blockbuster biologics lose exclusivity, enabling manufacturers to capture significant market share. Healthcare policy reforms increasingly favor biosimilar adoption through formulary preferences, reference pricing systems, and physician incentive programs that promote value-based care delivery. Market maturation reflects growing physician acceptance and patient confidence, driven by extensive real-world evidence demonstrating therapeutic equivalence and safety profiles comparable to reference biologics. Emerging markets represent substantial growth opportunities as healthcare infrastructure development coincides with rising disease burden and improved access to specialized treatments. Manufacturing technology advancement enables cost-effective production scaling, while strategic partnerships between pharmaceutical companies and healthcare systems facilitate market penetration.

The biosimilars market is segmented by product type, reflecting the specific originator biologics that have lost patent exclusivity, thereby opening avenues for biosimilar development. Monoclonal Antibodies (mAbs) currently constitute the largest and fastest-growing segment. This dominance stems from the expiration of patents for blockbuster antibody drugs used to treat a wide array of conditions, including various cancers, autoimmune disorders, and inflammatory diseases. Biosimilar mAbs offer significant cost savings, enhancing patient access to critical therapies that were previously prohibitively expensive, thereby driving their rapid adoption in healthcare systems worldwide. Insulin biosimilars form another crucial segment, primarily driven by the escalating prevalence of diabetes. With millions of people requiring daily insulin injections, biosimilar versions of various insulin types provide more affordable alternatives to the originator products. This increased accessibility is vital for diabetes management, especially in low- and middle-income countries, and significantly contributes to healthcare cost containment. Erythropoietin (EPO) biosimilars address anemia, particularly in patients with chronic kidney disease or those undergoing chemotherapy. EPO stimulates red blood cell production, and its biosimilar versions offer a cost-effective treatment option, improving the quality of life for a large patient population while reducing healthcare expenditures. Others segment encompasses a diverse range of biosimilar products, including other recombinant glycosylated and non-glycosylated proteins. This category includes granulocyte colony-stimulating factors, growth hormones, interferons, and other complex protein-based therapies.

Oncology is the largest and fastest-growing application segment, driven by the increasing incidence of cancer and the high cost of pioneering cancer biologics. Biosimilars of monoclonal antibodies are revolutionizing cancer treatment by improving patient access to life-saving therapies for breast cancer, colorectal cancer, non-Hodgkin lymphoma, and more, significantly alleviating financial burdens on healthcare systems and patients. Chronic & Autoimmune Disorders represent the second largest application area, experiencing substantial growth due to the rising prevalence of conditions like rheumatoid arthritis, psoriasis, Crohn's disease, and multiple sclerosis. Biosimilars of blockbuster drugs such as adalimumab, infliximab, and etanercept provide more affordable treatment options, making long-term management of these debilitating conditions more accessible and sustainable for millions of patients worldwide. Blood Disorders are another significant application for biosimilars, primarily driven by the use of erythropoietin (EPO) biosimilars to treat anemia associated with chronic kidney disease and chemotherapy-induced anemia. These biosimilars help manage the severe effects of blood disorders efficiently and cost-effectively. Growth Hormonal Deficiency is addressed by biosimilar versions of human growth hormone, offering essential treatment for children and adults suffering from growth disorders. These biosimilars improve quality of life by enabling normal growth and development while being more economically viable. The Infectious Disease segment is also gaining traction, particularly with biosimilars of interferons and other biologics used to combat various viral infections. While smaller, the potential for biosimilars in this area is significant, especially in regions with high disease burdens.

In-house manufacturing refers to biosimilar companies developing and producing their biosimilar products entirely within their own facilities and operational control. This approach offers several key benefits: greater control over the entire production process, from cell line development to final fill-and-finish, which is crucial for ensuring product quality, consistency, and comparability to the reference biologic. In-house manufacturing also allows for better protection of proprietary manufacturing processes and intellectual property, potentially leading to higher profit margins by eliminating third-party fees. Many established pharmaceutical and biotechnology companies with significant capital investment and existing biomanufacturing capabilities choose this route, enabling them to optimize production, reduce costs over the long term, and expedite market entry for their biosimilars. Contract Research and Manufacturing Services (CRAMS), also known as Contract Development and Manufacturing Organizations (CDMOs), involve biosimilar companies outsourcing parts or the entirety of their development and manufacturing processes to specialized third-party organizations. This model is particularly beneficial for smaller biotech firms or traditional generic drug manufacturers entering the complex biosimilar space that may lack the extensive infrastructure, specialized expertise, or financial resources required for large-scale biologic manufacturing. The advantages of using CRAMS include reduced upfront capital expenditure, access to cutting-edge technology and specialized expertise, increased flexibility to scale production up or down, and faster time-to-market. The competitive landscape for biosimilars often drives companies to seek efficient manufacturing, and CDMOs play a vital role in providing this flexibility and specialized capacity, especially in regions like India and China, which are emerging as hubs for contract biomanufacturing due to lower operational costs and skilled workforce availability.




Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Biosimilars Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Monoclonal Antibodies
• Insulin
• Erythropoietin
• Others (Includes recombinant glycosylated and non-glycosylated proteins)

By Application
• Oncology
• Chronic & Autoimmune Disorders
• Blood Disorders
• Growth Hormonal Deficiency
• Infectious Disease
• Others (Filgrastim/Pegfilgrastim, Teriparatide, Somatropin, Etanercept)

By Manufacturer
• In-house
• Contract Research and Manufacturing Services

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to this industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.